Insulin Lispro Market Research Report 2023
Insulin Lispro Market Size By Type (Rapid-acting insulin, Short-acting insulin, Intermediate-acting insulin, Long-acting insulin), Application (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes), Patient Demographics (Pediatrics, Adults, Geriatrics) End-User (Hospitals & Clinics, Homecare, Research Institutes), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region Global Market Analysis and Forecast, 2023-2030
Insulin Lispro Market Synopsis
The Global Insulin Lispro Market size was reasonably estimated to be approximately USD 4,131.68 Million in 2023 and is poised to generate revenue over USD 6,292.91 Million by the end of 2030, projecting a CAGR of around 5.40% from 2023 to 2030.
The pharmaceutical industry sector that deals with the creation, marketing, and sale of insulin lispro products is known as the insulin lispro market. It covers the market supply, demand, and competition for insulin lispro, a particular kind of insulin used to treat diabetes.
- A synthetic form of insulin called insulin lispro is used to control diabetes. It is a quick-acting insulin simple, meaning it is intended to have a quicker beginning and more limited length of activity contrasted with ordinary human insulin.
- The structure of insulin lispro is similar to that of human insulin; however, the insulin molecule has been altered by reversing the positions of two amino acids proline and lysine. This change permits insulin lispro to be retained all the more rapidly after infusion, prompting a fast decrease in glucose levels.
- Pharmaceutical companies that produce and sell insulin lispro products make up the market. To increase insulin lispro's efficacy, ease of use, and patient adherence, these businesses invest in research and development. In addition, they compete with other manufacturers to maintain profitability and expand their market share.
Top Key Players Involved Are:
"Eli Lilly and Company (US), Sanofi (France), Novo Nordisk (Denmark), Biocon Limited (India), Mylan N.V. (US), Boehringer Ingelheim International GmbH (Germany), Wockhardt Ltd. (India), Lupin Pharmaceuticals Inc. (US), Bioton S.A. (Poland), Ypsomed AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), AstraZeneca PLC (UK), Merck & Co. Inc. (US), Johnson & Johnson Services Inc. (US), Insulet Corporation (US), MannKind Corporation (US), Gan & Lee Pharmaceuticals (China), Daiichi Sankyo (Japan), Huiyuan Pharmaceutical (China), Afrezza (US) and Other Major Players."
Insulin Lispro Market Trend Analysis
Increasing Number of Diabetes Cases
- The global market for insulin lispro is strongly influenced by the rising incidence of diabetes. Over time, there has been a steady rise in the global prevalence of diabetes. Factors like stationary ways of life, undesirable weight control plans, heftiness, and a maturing populace add to the ascent in diabetes cases.
- Diabetes is a persistent condition that requires long haul the board to forestall entanglements and keep up with ideal well-being. Insulin treatment is a foundation of diabetes executives, particularly for people with type 1 diabetes and some with type 2 diabetes. Also, there has been a shift in diabetes treatment strategies over the past few years, with a greater emphasis placed on initiating insulin therapy promptly.
- Hence, the market for insulin lispro is primarily driven by the rising incidence of diabetes around the world. With the rise in diabetes prevalence comes a greater need for proper diabetes treatment, which involves using insulin therapy like insulin lispro to regulate blood sugar levels and avoid problems.
Concentrate on Diabetes in Children and Teens
- Diabetes in kids and teenagers presents a critical open door in the insulin lispro market. Diabetes has been increasing worldwide among children and adolescents. In this age group, obesity, sedentary lifestyles, and unhealthy eating all contribute to the development of type 2 diabetes. As an autoimmune condition, type 1 diabetes can also be diagnosed in childhood or adolescence.
- Youngsters and teenagers with diabetes have exceptional difficulties in dealing with their condition. Insulin treatment is commonly the backbone of treatment for these people. For kids and teenagers with diabetes, effective diabetes care is essential to avert complications, promote healthy growth, and guarantee a high quality of life.
- In conclusion, the focus on diabetes in kids and teenagers provides a significant market opportunity for insulin lispro. Manufacturers can cater to the unique needs of this demographic, enhance diabetes control, and encourage steadfast patient loyalty by creating customized insulin products, pediatric-friendly delivery methods, instructional materials, and support programs.
Segmentation Analysis of Insulin Lispro Market
Insulin Lispro market segments cover the Type, Application, Patient Demographics, End-user, and Distribution Channel. By Type, the Rapid-acting insulin segment is Anticipated to Dominate the Market Over the Forecast Period.
- Compared to other forms of insulin, rapid-acting insulins, such as insulin lispro, have a quicker beginning of action and a shorter duration. They are intended to quickly manage blood sugar levels by stimulating the body's normal insulin response following a meal. Because of this quality, rapid-acting insulins are extremely successful at controlling postprandial glucose levels, a critical component of diabetes care.
- High blood sugar levels after meals, or postprandial hyperglycemia, are a frequent problem in managing diabetes, especially in people with type 1 and some type 2 diabetes. To solve this issue, rapid-acting insulins, such as insulin lispro, rapidly drop blood sugar levels after meals. They are therefore frequently chosen to achieve precise postprandial glucose management.
- In conclusion, the market for insulin lispro is anticipated to be dominated over the forecast period by the rapid-acting insulin segment, its rapid onset, ability to manage postprandial hyperglycemia, flexibility in dose, and compatibility with insulin pump therapy all contribute to its widespread use and patient favor.
Regional Analysis of Insulin Lispro Market
Asia Pacific is Expected to Dominate the Market Over the Forecast Period.
- The prevalence of diabetes is significantly rising in the Asia Pacific region. Urbanization, sedentary behavior, poor diets, and genetic susceptibility are some of the factors that contribute to the increased prevalence of diabetes in the region's nations.
- Many people are living in Asia Pacific, including many densely populated nations like China and India. The market potential for insulin lispro is large given the size of the population who are either at risk of or have been diagnosed with diabetes.
- Rapid economic expansion is taking place in several Asia-Pacific nations, raising living standards and driving up healthcare costs. People have easier access to healthcare services, such as diabetes management, when disposable incomes rise.
- Based on these elements, the region's dominance in the market is a result of several factors, including the rising prevalence of diabetes, the region's sizable population, economic expansion, improved healthcare infrastructure, rising desire for personalized medicine, rising awareness, and initiatives to increase healthcare access.
Source - Statista
From above graph, it shows that several countries in the Asia Pacific region, such as China, India, Pakistan, Indonesia, Bangladesh & Japan have significantly high numbers of individuals with diabetes. This suggests that the Asia Pacific region is expected to dominate the Insulin Lispro market. These countries' large diabetic populations indicate a strong demand for diabetes management and treatment options, including insulin therapies like Insulin Lispro.
Covid-19 Impact Analysis on Insulin Lispro Market
- The pandemic caused changes in healthcare priorities, with an emphasis on resolving issues related to COVID-19. Healthcare resources were temporarily diverted from handling COVID-19 cases to non-urgent healthcare services, such as normal diabetes control and regular follow-ups.
- Hospital admissions, outpatient visits, and access to healthcare facilities were disrupted, which may have had an impact on how quickly diabetic patients started or adjusted their insulin therapy, including the usage of insulin lispro.
- Healthcare systems are resuming routine operations as nations make progress towards recovery and immunization campaigns advance. This period of recovery offers a chance for the insulin lispro market to recover and acquire traction.
- The recovery and expansion of the insulin lispro market are anticipated to be aided by initiatives to deal with postponed treatments, reinstate routine diabetic care, and enhance accessibility to diabetes management.
Top Key Players Covered in Insulin Lispro Market
- Eli Lilly and Company (US)
- Sanofi (France)
- Novo Nordisk (Denmark)
- Biocon Limited (India)
- Mylan N.V. (US)
- Boehringer Ingelheim International GmbH (Germany)
- Wockhardt Ltd. (India)
- Lupin Pharmaceuticals Inc. (US)
- Bioton S.A. (Poland)
- Ypsomed AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- AstraZeneca PLC (UK)
- Merck & Co. Inc. (US)
- Johnson & Johnson Services Inc. (US)
- Insulet Corporation (US)
- MannKind Corporation (US)
- Gan & Lee Pharmaceuticals (China)
- Daiichi Sankyo (Japan)
- Huiyuan Pharmaceutical (China)
- Afrezza (US) and Other Major Players.
Key Industry Developments in the Insulin Lispro Market
In June 2023, Eli Lilly and Company renewed its relationship with Team USA and announced a partnership with the LA28 Olympic and Paralympic Games. Lilly served as an official Team USA partner in prescription medicine and health equity through 2028, bringing expertise and experience to support elite athletes on their health journey to the Olympic and Paralympic Games.
In April 2023, Sanofi announced that it had completed its acquisition of Provention Bio, Inc. The acquisition added TZIELD, an innovative, fully owned, first-in-class therapy in type 1 diabetes, to Sanofi's core asset portfolio in General Medicines and further drove its strategic shift toward products with a differentiated profile.
|
Global Insulin Lispro Market |
|||
|
Base Year: |
2022 |
Forecast Period: |
2023-2030 |
|
Historical Data: |
2016 to 2021 |
Market Size in 2023: |
USD 4,131.68 Mn. |
|
Forecast Period 2023-30 CAGR: |
5.40% |
Market Size in 2030: |
USD 6,292.91 Mn. |
|
Segments Covered: |
By Type |
|
|
|
By Application |
|
||
|
By Patient Demographics |
|
||
|
By End-User |
|
||
|
By Distribution Channel |
|
||
|
By Region |
|
||
|
Global Insulin Lispro Market |
|||
|
Base Year: |
2022 |
Forecast Period: |
2023-2030 |
|
Historical Data: |
2016 to 2021 |
Market Size in 2023: |
USD 4,131.68 Mn. |
|
Forecast Period 2023-30 CAGR: |
5.40% |
Market Size in 2030: |
USD 6,292.91 Mn. |
|
Segments Covered: |
By Type |
|
|
|
By Application |
|
||
|
By Patient Demographics |
|
||
|
By End-User |
|
||
|
By Distribution Channel |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the Report: |
|
||
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
3.3 By Patient Demographics
3.4 By End-User
3.5 By Distribution Channel
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle
Frequently Asked Questions
What would be the forecast period in the Insulin Lispro Market research report?
The forecast period in the Insulin Lispro Market research report is 2023-2030.
Who are the key players in Insulin Lispro Market?
Eli Lilly and Company (US), Sanofi (France), Novo Nordisk (Denmark), Biocon Limited (India), Mylan N.V. (US), Boehringer Ingelheim International GmbH (Germany), Wockhardt Ltd. (India), Lupin Pharmaceuticals Inc. (US), Bioton S.A. (Poland), Ypsomed AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), AstraZeneca PLC (UK), Merck & Co. Inc. (US), Johnson & Johnson Services Inc. (US), Insulet Corporation (US), MannKind Corporation (US), Gan & Lee Pharmaceuticals (China), Daiichi Sankyo (Japan), Huiyuan Pharmaceutical (China), Afrezza (US) and Other Major Players.
What are the segments of the Insulin Lispro Market?
The Insulin Lispro Market is segmented into Type, Application, Patient Demographics, End-User, Distribution Channel, and region. By Type, the market is categorized into Rapid-acting insulin, Short-acting insulin, Intermediate-acting insulin, Long-acting insulin. By Application, the market is categorized into Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes. By Patient Demographics, the market is categorized into Pediatrics, Adults, Geriatrics. By End-User, the market is categorized into Hospitals & Clinics, Homecare, Research Institutes. By Distribution Channel, the market is categorized into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies. By region, it is analyzed across North America (U.S.; Canada; Mexico), Eastern Europe (Bulgaria; The Czech Republic; Hungary; Poland; Romania; Rest of Eastern Europe), Western Europe (Germany; UK; France; Netherlands; Italy; Russia; Spain; Rest of Western Europe), Asia Pacific (China; India; Japan; South Korea; Malaysia; Thailand; Vietnam; The Philippines; Australia; New-Zealand; Rest of APAC), Middle East & Africa (Turkey; Bahrain; Kuwait; Saudi Arabia; Qatar; UAE; Israel; South Africa), South America (Brazil; Argentina; Rest of SA)
What is the Insulin Lispro Market?
The pharmaceutical industry sector that deals with the creation, marketing, and sale of insulin lispro products is known as the insulin lispro market. It covers the market supply, demand, and competition for insulin lispro, a particular kind of insulin used to treat diabetes. A synthetic form of insulin called insulin lispro is used to control diabetes. It is a quick-acting insulin simple, meaning it is intended to have a quicker beginning and more limited length of activity contrasted with ordinary human insulin.
How big is the Insulin Lispro Market?
The Global Insulin Lispro Market size was reasonably estimated to be approximately USD 4,131.68 Million in 2023 and is poised to generate revenue over USD 6,292.91 Million by the end of 2030, projecting a CAGR of around 5.40% from 2023 to 2030.
